Live
- UpStudy: The Smart Solution for Homework Hassles
- Actress Rithika and models inaugurate Sutraa Lifestyle Exhibition
- Loud campaign
- Faculty students celebrated english literature day in Government Degree College
- Huge fire accident.. Shops of street vendors burnt in the fire
- Pawan Kalyan promises to protect the coastal area from sea erosion
- EC Transfers Two Senior IPS Officers in AP ahead of Elections
- DMK analysis predicts victory for INDIA bloc in TN but concedes gains for BJP and NDA too
- India showcasing innovative technologies at World Energy Congress
- IPL 2024: Mitchell comes in for Ravindra as Lucknow opt to bowl first against Chennai
Suven gets patents on neurological molecule
Suven Life Sciences has been granted a patent each from Hong Kong and the US and two from India for treatment of disorders associated with neurodegenerative diseases.
Hyderabad: Suven Life Sciences has been granted a patent each from Hong Kong and the US and two from India for treatment of disorders associated with neurodegenerative diseases.
These patents are valid till 2032, 2030 and 2034 respectively, according to a communique the company said in a BSE filing. The market capitalisation of the company surged by Rs94 crore to Rs2,522.10 crore.
Suven Life CEO Venkat Jasti said: “We’re very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
The granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment.
